Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FranceBack to France

Clinical trials in Bois-Guillaume – page 48

671 clinical trials in Bois-Guillaume, France across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Bois-Guillaume at a glance
671
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

671 trials in Bois-Guillaume

Open in trial search

B-cell lymphoma+1

Not recruiting

Study of Axi-Cel, Fludarabine Phosphate, and Cyclophosphamide for Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma Ineligible for Stem Cell Transplant

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:LYSARC

Hidradenitis

Not recruiting

Study on the Effectiveness of Ianalumab for Treating Moderate to Severe Hidradenitis Suppurativa in Patients

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Ianalumab
  • Sponsor:Novartis Pharma AG

Dermatitis atopic

Not recruiting

Study on the Effectiveness and Safety of Lebrikizumab for Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis

Registered drug
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Lebrikizumab
  • Sponsor:Almirall S.A.

Hidradenitis

Not recruiting

Study on the Long-Term Safety of Povorcitinib for Patients with Moderate to Severe Hidradenitis Suppurativa

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Povorcitinib
  • Sponsor:Incyte Corp.

Transitional cell cancer of the renal pelvis and ureter+1

Not recruiting

Study on the Safety and Effectiveness of Padeliporfin Therapy for Patients with Low-Grade Upper Tract Urothelial Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Padeliporfin
  • Sponsor:Steba Biotech S.A.

Diffuse large B-cell lymphoma

Not recruiting

Study on the Safety and Effectiveness of Glofitamab with R-CHOP for High-Risk Patients with Untreated Diffuse Large B-Cell Lymphoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Glofitamab
  • Sponsor:F. Hoffmann-La Roche AG

Non-Hodgkin's lymphoma+13

Not recruiting

Study of Long-term Safety of Tazemetostat in Patients Who Previously Participated in Tazemetostat Clinical Trials

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Tazemetostat
  • Sponsor:Epizyme Inc.

Non-small cell lung cancer

Not recruiting

Study of Selpercatinib for Patients with Early-Stage RET Fusion-Positive Non-Small Cell Lung Cancer After Local Treatment

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Selpercatinib
  • Sponsor:Eli Lilly & Co.

Colorectal cancer metastatic

Not recruiting

Study on the Effect of Post-Surgery Chemotherapy with Irinotecan and Drug Combination for Patients with Colorectal Cancer and Liver Metastases

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Assistance Publique Hopitaux De Paris

Uveitis

Not recruiting

Study on the Effectiveness of Baricitinib for Patients with Refractory Non-Infectious Uveitis

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Baricitinib
  • Sponsor:Centre Hospitalier Universitaire Rouen

Macular telangiectasia

Not recruiting

Study Comparing Aflibercept and Placebo for Patients with Macular Telangiectasia Type 1

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:Centre Hospitalier Universitaire De Dijon

Dermatitis atopic

Not recruiting

Study on Amlitelimab for Patients Aged 12 and Older with Moderate to Severe Atopic Dermatitis Using Topical Corticosteroids and Inadequate Response to Previous Treatments

Registered drug
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Amlitelimab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Other cities in France

The busiest research cities in the country

All 366 cities in France

Clinical research in Bois-Guillaume

What the registry says about research in the country

01 Kidney Disease & Transplantation

Innovative research focusing on chronic kidney disease treatments and transplant outcomes, including studies of novel medications like baxdrostat and tegoprubart for improving patient care.

  • Kidney Transplant Rejection Prevention
  • CKD Management
  • Hypertension Control

Multiple trials evaluating new therapeutic approaches for transplant recipients and CKD patients.

02 Blood Disorders

Clinical investigations into treatments for various blood-related conditions, with emphasis on immune thrombocytopenia and thrombotic disorders.

  • Thrombotic Thrombocytopenic Purpura
  • Hemolytic Uremic Syndrome
  • Immunological Therapies

Advanced studies combining established and experimental treatments for better patient outcomes.

03 Infectious Disease Management

Research examining treatment strategies for viral infections and optimization of antibiotic therapy, particularly in elderly populations.

  • Cytomegalovirus Treatment
  • Antibiotic Management
  • Viral Pneumonia

Studies focused on improving treatment protocols and reducing antibiotic overuse.

04 Autoimmune Conditions

Investigation of novel therapies for vasculitis and related autoimmune disorders, including targeted biological treatments.

  • Takayasu Arteritis
  • ANCA-Associated Vasculitis
  • Goodpasture Disease

Evaluating new treatment combinations to improve disease management and patient outcomes.

Back to FranceAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.